AR128463A1 - Uso de un agonista del receptor de melanocortina-4 en la prevención o el tratamiento de obesidades genéticas raras - Google Patents
Uso de un agonista del receptor de melanocortina-4 en la prevención o el tratamiento de obesidades genéticas rarasInfo
- Publication number
- AR128463A1 AR128463A1 ARP230100283A ARP230100283A AR128463A1 AR 128463 A1 AR128463 A1 AR 128463A1 AR P230100283 A ARP230100283 A AR P230100283A AR P230100283 A ARP230100283 A AR P230100283A AR 128463 A1 AR128463 A1 AR 128463A1
- Authority
- AR
- Argentina
- Prior art keywords
- prevention
- treatment
- rare genetic
- pharmaceutically acceptable
- obesities
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 4
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 abstract 6
- 239000000683 Pro-Opiomelanocortin Substances 0.000 abstract 6
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 6
- 208000036391 Genetic obesity Diseases 0.000 abstract 4
- 208000037493 inherited obesity Diseases 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000007812 deficiency Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20220016377 | 2022-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128463A1 true AR128463A1 (es) | 2024-05-08 |
Family
ID=87564659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100283A AR128463A1 (es) | 2022-02-08 | 2023-02-07 | Uso de un agonista del receptor de melanocortina-4 en la prevención o el tratamiento de obesidades genéticas raras |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250134898A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4461297A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505229A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230120106A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119300835A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128463A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023218785A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248118A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002389A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024011882A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009854A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI838114B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023153762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3202315A1 (en) * | 2020-12-22 | 2022-06-30 | Hee Dong Park | Use as selective agonist of malanocortin-4 receptor |
| KR20250046623A (ko) * | 2023-09-27 | 2025-04-03 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| US12516047B2 (en) * | 2019-11-07 | 2026-01-06 | Lg Chem, Ltd. | Melanocortin-4 receptor agonists |
| CN116507615A (zh) * | 2020-10-29 | 2023-07-28 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物的晶型i及其制备方法 |
| TWI804170B (zh) * | 2021-01-21 | 2023-06-01 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑的用途 |
| TWI826938B (zh) * | 2021-02-26 | 2023-12-21 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑 |
| TWI861780B (zh) * | 2022-03-28 | 2024-11-11 | 南韓商Lg化學股份有限公司 | 預防或治療肥胖的聯合療法 |
-
2023
- 2023-02-06 TW TW112104117A patent/TWI838114B/zh active
- 2023-02-07 US US18/837,125 patent/US20250134898A1/en active Pending
- 2023-02-07 EP EP23753110.8A patent/EP4461297A4/en active Pending
- 2023-02-07 CN CN202380032193.6A patent/CN119300835A/zh active Pending
- 2023-02-07 CA CA3248118A patent/CA3248118A1/en active Pending
- 2023-02-07 JP JP2024547302A patent/JP2025505229A/ja active Pending
- 2023-02-07 KR KR1020230016160A patent/KR20230120106A/ko not_active Ceased
- 2023-02-07 AR ARP230100283A patent/AR128463A1/es unknown
- 2023-02-07 AU AU2023218785A patent/AU2023218785A1/en active Pending
- 2023-02-07 WO PCT/KR2023/001712 patent/WO2023153762A1/ko not_active Ceased
-
2024
- 2024-08-08 CL CL2024002389A patent/CL2024002389A1/es unknown
- 2024-08-12 MX MX2024009854A patent/MX2024009854A/es unknown
- 2024-08-30 CO CONC2024/0011882A patent/CO2024011882A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025505229A (ja) | 2025-02-21 |
| AU2023218785A1 (en) | 2024-08-22 |
| CA3248118A1 (en) | 2025-01-24 |
| WO2023153762A1 (ko) | 2023-08-17 |
| EP4461297A4 (en) | 2025-04-09 |
| CL2024002389A1 (es) | 2025-01-31 |
| TW202339761A (zh) | 2023-10-16 |
| CN119300835A (zh) | 2025-01-10 |
| CO2024011882A2 (es) | 2025-01-23 |
| TWI838114B (zh) | 2024-04-01 |
| EP4461297A1 (en) | 2024-11-13 |
| US20250134898A1 (en) | 2025-05-01 |
| KR20230120106A (ko) | 2023-08-16 |
| MX2024009854A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002538A (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t. | |
| DOP2020000058A (es) | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas | |
| MX2023000798A (es) | Peptidos funcionalizados como agentes antivirales. | |
| RU2009137607A (ru) | Композиции и наборы для лечения гриппа | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
| AR050463A1 (es) | Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer. | |
| DOP2024000088A (es) | Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| MX2025005933A (es) | Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il)butan-2-il)benzamida como inhibidores de la proteasa para el tratamiento o la prevencion de la infeccion por coronavirus | |
| GEAP202516765A (en) | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof | |
| CO2024011882A2 (es) | Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidad | |
| CO2025004701A2 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| DOP2022000107A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| CO2024002712A2 (es) | Azálidos inmunomoduladores | |
| MX2023008098A (es) | Uso de agonista del receptor de melanocortina-4. | |
| PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| ZA202102241B (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| AR122450A1 (es) | Compuestos de (trifluorometil)pirimidin-2-amina | |
| GEP20257771B (en) | Compounds and compositions as sppl2a inhibitors | |
| MX2022014461A (es) | Nuevos abridores de canales de potasio maxi-k para el tratamiento de trastornos asociados con x fragil. | |
| AR134364A1 (es) | Compuestos antivirales de indolinilo y sus usos | |
| AR133526A1 (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| JP2019515025A5 (cg-RX-API-DMAC7.html) | ||
| AR127582A1 (es) | Métodos para el tratamiento del cáncer |